Biogened Past Earnings Performance
Past criteria checks 4/6
Biogened has been growing earnings at an average annual rate of 29.5%, while the Pharmaceuticals industry saw earnings growing at 10.4% annually. Revenues have been growing at an average rate of 18.5% per year. Biogened's return on equity is 11.7%, and it has net margins of 4.4%.
Key information
29.5%
Earnings growth rate
30.3%
EPS growth rate
Pharmaceuticals Industry Growth | 29.4% |
Revenue growth rate | 18.5% |
Return on equity | 11.7% |
Net Margin | 4.4% |
Next Earnings Update | 15 May 2024 |
Recent past performance updates
Recent updates
Biogened's (WSE:BGD) Promising Earnings May Rest On Soft Foundations
Feb 21Is Biogened (WSE:BGD) A Risky Investment?
Feb 01Biogened S.A. (WSE:BGD) Looks Just Right With A 37% Price Jump
Feb 01We Think Biogened (WSE:BGD) Can Stay On Top Of Its Debt
Jun 30Biogened (WSE:BGD) Seems To Use Debt Quite Sensibly
Oct 08Is Biogened (WSE:BGD) A Risky Investment?
Jun 29Does Biogened (WSE:BGD) Have A Healthy Balance Sheet?
Mar 25These 4 Measures Indicate That Biogened (WSE:BGD) Is Using Debt Reasonably Well
Dec 09Biogened (WSE:BGD) Has A Somewhat Strained Balance Sheet
Jul 29Biogened (WSE:BGD) Seems To Use Debt Quite Sensibly
Apr 30Is Biogened (WSE:BGD) A Risky Investment?
Jan 24Revenue & Expenses BreakdownBeta
How Biogened makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 96 | 4 | 55 | 0 |
30 Sep 23 | 92 | 4 | 47 | 0 |
30 Jun 23 | 90 | 4 | 46 | 0 |
31 Mar 23 | 85 | 3 | 46 | 0 |
31 Dec 22 | 80 | 3 | 42 | 0 |
30 Sep 22 | 77 | 4 | 41 | 0 |
30 Jun 22 | 72 | 4 | 36 | 0 |
31 Mar 22 | 70 | 3 | 36 | 0 |
31 Dec 21 | 65 | 2 | 35 | 0 |
30 Sep 21 | 57 | 2 | 33 | 0 |
30 Jun 21 | 54 | 2 | 33 | 0 |
31 Mar 21 | 50 | 1 | 30 | 0 |
31 Dec 20 | 48 | 1 | 30 | 0 |
30 Sep 20 | 49 | 2 | 29 | 0 |
30 Jun 20 | 48 | 1 | 29 | 0 |
31 Mar 20 | 48 | 1 | 29 | 0 |
31 Dec 19 | 47 | 1 | 28 | 0 |
30 Sep 19 | 45 | 1 | 28 | 0 |
30 Jun 19 | 44 | 1 | 27 | 0 |
31 Mar 19 | 41 | 1 | 26 | 0 |
31 Dec 18 | 40 | 1 | 26 | 0 |
30 Sep 18 | 39 | 1 | 24 | 0 |
30 Jun 18 | 39 | 1 | 24 | 0 |
31 Mar 18 | 36 | 1 | 22 | 0 |
31 Dec 17 | 34 | 1 | 21 | 0 |
30 Sep 17 | 30 | 1 | 19 | 0 |
30 Jun 17 | 31 | 1 | 20 | 0 |
31 Mar 17 | 29 | 1 | 19 | 0 |
31 Dec 16 | 29 | 1 | 19 | 0 |
30 Sep 16 | 32 | 2 | 21 | 0 |
30 Jun 16 | 31 | 2 | 20 | 0 |
31 Mar 16 | 31 | 3 | 19 | 0 |
31 Dec 15 | 30 | 3 | 18 | 0 |
30 Sep 15 | 30 | 2 | 18 | 0 |
30 Jun 15 | 26 | 1 | 15 | 0 |
31 Mar 15 | 24 | 1 | 14 | 0 |
31 Dec 14 | 23 | 1 | 13 | 0 |
30 Sep 14 | 20 | 1 | 12 | 0 |
30 Jun 14 | 21 | 1 | 12 | 0 |
31 Mar 14 | 22 | 1 | 13 | 0 |
31 Dec 13 | 22 | 2 | 12 | 0 |
30 Sep 13 | 24 | 2 | 12 | 0 |
30 Jun 13 | 24 | 2 | 18 | 0 |
Quality Earnings: BGD has high quality earnings.
Growing Profit Margin: BGD's current net profit margins (4.4%) are higher than last year (4.2%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: BGD's earnings have grown significantly by 29.5% per year over the past 5 years.
Accelerating Growth: BGD's earnings growth over the past year (24.3%) is below its 5-year average (29.5% per year).
Earnings vs Industry: BGD earnings growth over the past year (24.3%) exceeded the Pharmaceuticals industry 3.8%.
Return on Equity
High ROE: BGD's Return on Equity (11.7%) is considered low.